Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management

Open access
Luck, Suzanne E., Wieringa, Jantien W., Blázquez-Gamero, Daniel, Henneke, Philipp, Schuster, Katharina, Butler, Karina, Capretti, Maria Grazia, Cilleruelo, Maria José, Curtis, Nigel, Garofoli, Francesca, Heath, Paul, Iosifidis, Elias, Klein, Nigel, Lombardi, Giuseppina, Lyall, Hermione, Nieminen, Tea, Pajkrt, Dasja, Papaevangelou, Vassiliki, Posfay-Barbe, Klara, Puhakka, Laura, Roilides, Emmanuel, Rojo, Pablo, Saavedra-Lozano, Jesús, Shah, Teshri, Sharland, Mike, Saxen, Harri, Vossen, Ann C.T.M·2017·Pediatric Infectious Disease Journal

Abstract

Congenital cytomegalovirus (cCMV) is the most common congenital infection in the developed world. Reported prevalence varies between cohorts but is approximately 7 per 1000 births.1 About half of cytomegalovirus (CMV)-infected babies with clinically detectable disease at birth are destined to have significant impairments in their development, and cCMV infection is implicated in approximately 25% of all children with sensorineural hearing loss (SNHL).1,2 Meta-analysis shows that although long-term sequelae, especially SNHL, are more common in those with clinically detectable disease at birth, they are also found in 13% of those without clinical features attributable to CMV on initial examination.1 Despite the significant long-term impact of cCMV infection, there is limited evidence on which to base many treatment decisions in clinical practice. In an era of enhanced perinatal screening, fetuses and newborns are increasingly tested for CMV after abnormalities were detected during routine ultrasonography or maternal serology. Furthermore, otherwise “asymptomatic”, congenitally CMV-infected, newborns are being identified after detection of SNHL through newborn hearing screening programs. Because of earlier diagnosis, babies with cCMV now presenting to pediatricians differ from those primarily included in clinical trials of treatment reported in the literature. A symposium was convened during the 2015 conference of the European Society of Paediatric Infectious Diseases to discuss the current management of cCMV. In attendance were clinicians from throughout Europe, many of whom are involved in policy for cCMV for their region/country. This article summarizes the discussions at this meeting alongside the evidence informing them. A balanced perspective of the controversies in this area is presented and areas of consensus highlighted. Finally, where evidence is lacking, suggestions are made for future research efforts to address areas of unmet medical need. The authors acknowledge the coexisting need for studies on the management of babies with symptoms consistent with cCMV, but in whom this diagnosis cannot be firmly established, and of those with symptomatic postnatal CMV infection; this article does not, however, address these groups. The internationally accepted GRADE system for evaluating evidence has been used to illustrate points where relevant (Table 1).3TABLE 1.: Grade System of Evaluating Evidence3DEFINITIONS OF SYMPTOMATIC DISEASE Classically, cCMV infection is categorized as “symptomatic” or “asymptomatic” at birth. Differing definitions and opinions on what constitutes “symptomatic” CMV infection, however, makes interpreting the literature challenging. Indeed, some of the largest cohort studies include babies with SNHL at birth in the group described as being “asymptomatic” because no “clinically apparent disease” was detectable during newborn examination.4 In modern healthcare systems, whereby cCMV is increasingly detected through screening for other conditions, alongside increased accessibility of investigations, such as magnetic resonance imaging (MRI), the traditional dichotomy between clinically “apparent” and “inapparent” disease is becoming less meaningful. Table 2 summarizes the accepted clinical features of cCMV disease with those symptoms detectable on newborn examination listed separately to those detectable only if specific investigations are conducted, for example, when cCMV is already suspected.5–8TABLE 2.: Possible Signs and Symptoms in Children With Congenital CMV5–8Full Consensus Within This Expert Group Was That 1. For the purposes of research and publication, newborns identified as having cCMV disease after abnormal clinical examination at birth (such as microcephaly, small for gestational age (SGA), widespread petechiae, hepatosplenomegaly) should be differentiated from those babies identified through screening or investigation for other disorders, for example, those tested for CMV after known/likely maternal infection or abnormal newborn hearing screening. This differentiation would allow for more accurate assessment of the prognostic value of individual manifestations of “symptomatic” disease on longer-term outcomes as already shown in other publications.9 2. “Symptomatic” cCMV should be considered as “severe,” “moderate” or “mild” disease. a. “Mild” disease includes those with isolated (1 or 2 at most), otherwise, clinically insignificant or transient findings, such as petechiae, mild hepatomegaly or splenomegaly or biochemical/hematologic abnormalities (such as thrombocytopenia, anemia, leukopenia, borderline raised liver enzyme abnormalities or conjugated hyperbilirubinemia) or SGA (defined as weight for gestational age <−2 standard deviations) without microcephaly. b. “Severe” disease includes those with central nervous system (CNS) involvement (abnormal neurologic or ophthalmologic examination, microcephaly or neuroimaging consistent with cCMV disease [such as calcifications,

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/inf.0000000000001763

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Metadata

Authors
Luck, S. E., Wieringa, J. W., Blázquez-Gamero, D., Henneke, P., Schuster, K., Butler, K., Capretti, M. G., Cilleruelo, M. J., Curtis, N., Garofoli, F., Heath, P., Iosifidis, E., Klein, N., Lombardi, G., Lyall, H., Nieminen, T., Pajkrt, D., Papaevangelou, V., Posfay-Barbe, K., Puhakka, L., Roilides, E., Rojo, P., Saavedra-Lozano, J., Shah, T., Sharland, M., Saxen, H., & Vossen, A. C. T. M.
Venue
Pediatric Infectious Disease Journal
Published
2017-12
Volume
36
Issue
12
Pages
1205-1213
ISSN
0891-3668 (ISSN-L)
OpenAlex
W2768602872
Cited by
309
References
38
FWCI
11.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. https://app.cochat.ai/papers/10.1097/inf.0000000000001763
The paper
Luck, S. E., Wieringa, J. W., Blázquez-Gamero, D., Henneke, P., Schuster, K., Butler, K., Capretti, M. G., Cilleruelo, M. J., Curtis, N., Garofoli, F., Heath, P., Iosifidis, E., Klein, N., Lombardi, G., Lyall, H., Nieminen, T., Pajkrt, D., Papaevangelou, V., Posfay-Barbe, K., . . . Vossen, A. C. T. M. (2017). Congenital Cytomegalovirus: A European Expert Consensus Statement on Diagnosis and Management. Pediatric Infectious Disease Journal. https://doi.org/10.1097/inf.0000000000001763

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.